The American Pharmacists Association (APhA), American Society of Consultant Pharmacists (ASCP), American Society of Health System Pharmacists (ASHP), National Alliance of State Pharmacy Associations (NASPA), and the National Community Pharmacists Association (NCPA) today issued the following statement in response to the FDA’s decision to authorize the Pfizer COVID-19 oral antiviral but specifically prevent pharmacists from writing the prescriptions: